摘要
细胞因子激活的杀伤(CIK)细胞及树突细胞诱导的细胞因子激活的杀伤(DC-CIK)细胞均是新型的异质性免疫效应细胞群,其主要的效应细胞同时表达CD3和CD56两种膜蛋白分子,兼有T淋巴细胞强大的抗肿瘤活性和自然杀伤细胞的非主要组织相容性复合体限制性杀瘤优点。其与传统治疗方法相结合,可以使患者获得更好的临床受益率、更高的生存率和更长的生存期,显著提高患者的生活质量;应用DC-CIK比单独CIK具有更大的优势,可以提高靶向性和增强杀伤能力。CIK及DC-CIK的免疫细胞治疗为非小细胞肺癌的治疗提供了新的途径。
Cytokine induced killer（CIK） cells and dendritic cells induced CIK（DC-CIK） cells are novel heterogeneous population of immune effector cells,which express two types of membrane proteins of CD3 and CD56,with the advantages of both T lymphocytes＇ antitumor activity and natural killer cells＇ a non-major histocompatibility complex restricted tumoricidal activity.Its combination with traditional therapies can achieve better clinical effects,higher survival rate and longer survival time,and significantly improved quality of life.DC-CIK is better than single application of CIK,since it can improve the targeting and killing ability.CIK and DC-CIK immune therapy provides a new approach for non-small cell lung cancer.
出处
《医学综述》
2013年第14期2568-2570,共3页
Medical Recapitulate
